NewsDesk @bactiman63
Specialty vaccine company, Valneva, announced that the U.S. Food and Drug Administration (FDA) has completed a filing review of its Biologics License Application for Valneva’s single-shot chikungunya vaccine candidate VLA1553 and has determined that the application is sufficiently complete to permit a substantive review. The review classification is Priority.
VLA1553 has been assigned a Prescription Drug User Fee Act (PDUFA) review goal date at the end of August 2023, which is the date by which the FDA intends to take action on the application. The FDA’s acknowledgement of filing does not mean that a license will be granted, nor does it represent any evaluation of the adequacy of the data submitted.
VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 100 countries. It has been designed by deleting a part of the chikungunya virus genome.
- Austria: HPV vaccination free of charge up to the age of 21
- Denmark reports three times the normal rate of group A streptococci cases
- Rabies in Bennettsville, S.C.: Six people and six stray cats exposed
- Martinique reports resurgence of dengue cases
- Most comprehensive study to date provides evidence on natural immunity protection by COVID-19 variant and how protection fades over time
- Dominican Republic: Officials ask people for voluntary hand-over of raccoon, Warns of health risks
- Measles in the Philippines: Cases up in Zamboanga Peninsula, CALBARZON, others
